Humaid Al-Shamsi, Chief Executive Officer at Burjeel Cancer Institute and Regional Director of Burjeel Oncology GCC at Burjeel Holdings, shared a post on LinkedIn:
“Humbled to be among the most published practicing physicians in the UAE/ GCC and within Burjeel Holdings , with 30 publications in 2025. With full 5 days a week clinics spanning 10-11 hours each.
The highlight of our work includes AI-based blood tests for early cancer detection in over 1,000 subjects, as well as studies on CAR-T therapies for solid tumors.
With 480+ citations from over 30+ countries and collaborations with 50+ researchers from 20+ countries—including top institutions -Dana-Farber Cancer Institute /Harvard University, Stanford University, The University of Texas M.D. Anderson Cancer Center , University of Toronto, Jazan University, and MD Anderson Cancer Center Madrid – Hospiten—this research is gaining international recognition while advancing our understanding of cancer.
Grateful to my colleagues at Burjeel Cancer Institute | BCI and Burjeel Holding and all collaborators, with the shared goal of improving cancer care globally.
Special thanks to my research manager Ms Faryal Iqbal.
Special thanks to my co-authors Hampig Raphael Kourie, Saeed Rafii , Deborah Mukherji , Vineet Datta , Sewanti Limaye, Ibrahim Abu-Gheida , Ahmad Abuhelwa, Muhammad Farooq Latif, Mary Bussell, Nadia Abdelwahed , Amin Abyad , Faryal Iqbal
Special thanks to Micheline Bakhos Varjabedian for the administrative support with our research activities with Emirates Oncology Society.
Grateful to my institutions :
- Burjeel Holdings
- Burjeel Cancer Institute | BCI
- Harvard Medical School
- RAK Medical & Health Sciences University
- Gulf Medical University
- Emirates Oncology Society
Our publications and abstracts are published at : Lancet Oncology 35.9, Annals of Oncology 65.4, Journal of Clinical Oncology 43.4, Blood Advances7.1, Cancers 4.4.”
Read more posts about Humaid Al-Shamsi on OncoDaily.